AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio
NORTH CHICAGO, Ill., Oct. 18, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that new and updated data from its broad solid tumor portfolio will be presented at the 2026 European Society for Medical Oncology (ESMO) Congress, taking place October 23-27 in Madrid, Spain. Spanning multiple tumor types, therapeutic modalities and stages of development, the presentations represent AbbVie's most expansive ESMO program to date.
Collectively, the findings across Temab-A (telisotuzumab adizutecan), ABBV-706, ABBV-969, ABBV-1480 (RC148), alveltamig, Elahere ® (mirvetuximab soravtansine-gynx) and Emrelis™ (telisotuzumab vedotin-tllv) demonstrate how AbbVie is leveraging its deep expertise in cancer biology to advance differentiated approaches that address the complexity and heterogeneity of solid tumors and help meet the diverse needs of cancer patients worldwide.
"The data we are presenting at ESMO reflects the progress being made through AbbVie's disciplined, biology-driven approach to oncology innovation," said Daejin Abidoye, vice president, therapeutic area head of oncology, solid tumor and hematology, AbbVie. "Across multiple tumor types and stages of development, we are seeing encouraging evidence of longer-term clinical benefit, promising outcomes in biomarker-defined patient populations, and the potential of novel combinations and next-generation platforms. Together, these findings reinforce our strategy of translating scientific insights into differentiated treatment approaches with the potential to meaningfully improve outcomes for patients living with cancer."
Selected findings from AbbVie's investigational solid tumor portfolio include updated clinical, survival and translational biomarker data across multiple antibody-drug conjugates (ADCs) and bispecific antibody programs, supporting continued development across a range of solid tumors:
Details on key presentations at ESMO 2026 are available below and the full abstracts are available through the congress online program.
Approved medicines and investigational assets referenced are being evaluated in ongoing clinical trials across multiple stages of development and disease areas, both as standalone therapies and in combination regimens. For more information on AbbVie's ongoing clinical trial programs, please visit ClinicalTrials.gov.
Note: All presentation times are listed in local Madrid time.
Abstract Title
Date/Time
Session
Abstract Number
Baseline molecular characterization and responses associated with ABBV-969 treatment in patients with metastatic castration-resistant prostate cancer
Friday, October 23, 2026
3:15—4:00 PM
Poster
Metastatic prostate cancer; Poster Area – Hall 5
2224P
Overall survival (OS) analysis of telisotuzumab adizutecan in patients (pts) with nonsquamous non-small cell lung cancer (NSQ NSCLC): Phase 1 first-in-human study
Saturday, October 24, 2026
09:27—09:32 AM
Rapid Oral
NSCLC, metastatic; Almeria Auditorium – Hall 9
2658RO
Long-term follow-up of Telisotuzumab Adizutecan (ABBV-400, Temab-A) in combination with bevacizumab (Bev) vs standard of care (SOC) in patients (pts) with 3L+ colorectal cancer (CRC): Updated results of a phase 1 study
Saturday, October 24, 2026
3:20—3:25 PM
Rapid Oral
Gastrointestinal Tumours, lower digestive; Alicante Auditorium – Hall 6
791RO
RC118 combined with RC148 (ABBV-1480) for advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA): updated results from a randomized Phase 2 trial
Sunday, October 25, 2026
12:00—12:45 PM
Poster
Oesophagogastric cancer; Poster Area – Hall 5
2910P
Telisotuzumab adizutecan (Temab-A) for EGFR-mutated (mut) nonsquamous non-small cell lung cancer (NSQ NSCLC): Post hoc analysis from a phase 1 first-in-human (FIH) study in patients (pts) with brain metastases (BMs)
Monday, October 26, 2026
12:00—12:45 PM
Poster
NSCLC, metastatic; Poster Area – Hall 5
2635P
Real world (RW) uptake and characteristics of patients (Pts) receiving telisotuzumab vedotin-tllv (Teliso-V) in non-small cell lung cancer (NSCLC) from a US Claims Database
Monday, October 26, 2026
12:00—12:45 PM
Poster
NSCLC, locally advanced; Poster Area – Hall 5
2583P
ABBV-706: A first-in-class SEZ6-targeted topoisomerase 1 inhibitor (Top1i)-antibody-drug conjugate (ADC) with robust antitumour activity in relapsed/refractory small cell lung cancer (R/R SCLC)
Monday, October 26, 2026
10:15—10:20AM
Rapid Oral
Non-metastatic NSCLC and other thoracic malignancies; Burgos Auditorium – Hall 3
3837RO
Characterization of responder outcomes in folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer (PROC): Phase 3 MIRASOL (GOG 3045/ENGOT-ov55)
Monday, October 26, 2026
12:00—12:45 PM
Poster
Gynaecological cancers; Poster Area – Hall 5
1268P
Assessment of mirvetuximab soravtansine (MIRV) vs investigator's choice chemotherapy (ICC) as first line of therapy in folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer (PROC) in MIRASOL (GOG 3045/ENGOT-ov55)
Monday, October 26, 2026
12:00—12:45 PM
Poster
Gynaecological cancers; Poster Area – Hall 5
1308P
Time to improvement in fatigue patient-reported outcomes (PRO) with mirvetuximab soravtansine (MIRV) vs investigator-choice chemotherapy (ICC) in platinum-resistant ovarian cancer (PROC)
Monday, October 26, 2026
12:00—12:45 PM
Poster
Gynaecological cancers; Poster Area – Hall 5
1332P
Hematologic safety of carboplatin (Carbo) plus mirvetuximab soravtansine (MIRV) in patients (pts) with folate receptor alpha (FRα)-expressing platinum-sensitive ovarian cancer (PSOC)
Monday, October 26, 2026
12:00—12:45 PM
Poster
Gynaecological cancers; Poster Area – Hall 5
1330P
FLORENZA: A phase 2, open-label, randomized study to evaluate safety, efficacy, and dose optimization of mirvetuximab soravtansine (MIRV) combination therapies for epithelial ovarian cancer (EOC)
Monday, October 26, 2026
12:00—12:45 PM
Poster
Gynaecological cancers: Poster Area – Hall 5
1342TiP
Updated overall survival results from the phase 1 dose escalation and expansion study of alveltamig (ZG006), a trispecific T cell engager targeting DLL3/DLL3/CD3, as monotherapy in patients with refractory small cell lung cancer or neuroendocrine carcinoma with longer follow up
Monday, October 26, 2026
12:00—12:45 PM
Poster
SCLC; Poster Area – Hall 5
3826P
RC148 (ABBV-1480) monotherapy or in combination with docetaxel in first- or second-line advanced non-small-cell lung cancer (NSCLC) without actionable genomic alterations (AGA): Updated results from a phase 1/2 study
Monday, October 26, 2026
12:00—12:45 PM
Poster
NSCLC, Metastatic; Poster Area – Hall 5
2669P
Temab-A, ABBV-706 and ABBV-969 are investigational medicines and are not approved by any health authority worldwide. Their safety and efficacy have not been established and are being evaluated in ongoing clinical studies.
AbbVie holds exclusive rights from RemeGen to develop, manufacture and commercialize ABBV-1480 outside of Greater China. ABBV-1480 is an investigational medicine and is being evaluated in ongoing clinical studies.
Alveltamig (ZG006) is an investigational medicine being developed by Suzhou Zelgen Biopharmaceuticals and has not been approved by any health authority worldwide.
U.S. Prescribing Information for AbbVie Medicines
Please see full Prescribing Information for ELAHERE ® (mirvetuximab soravtansine-gynx)
Please see full Prescribing Information for EMRELIS™ (telisotuzumab vedotin-tllv)
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.
About AbbVie in Oncology
AbbVie is committed to elevating standards of care and bringing transformative therapies to patients worldwide living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibodies and novel CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.
Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood cancers and solid tumors. We are evaluating more than 35 investigational medicines in multiple clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
Global Media:
Sourojit (Jit) Bhowmick, Ph.D.
Jit.Bhowmick@abbvie.com
Mabel Martinez
Mabel.Martinez@abbvie.com
Investors:
Liz Shea
Liz.Shea@abbvie.com
1 Cecchini M, Cruz-Correa M, Han S, et al. "Long-term follow up of Telisotuzumab Adizutecan (ABBV-400, Temab-A) in combination with bevacizumab (Bev) vs standard of care (SOC) in patients (pts) with 3L+ colorectal cancer (CRC): Updated results of a phase 1 study." Abstract presented at European Society for Medical Oncology Congress, 2026. Madrid, Spain.
2 Raimbourg J, Camidge R, Kim T, et al. " Telisotuzumab adizutecan (Temab-A) for EGFR-mutated (mut) nonsquamous non-small cell lung cancer (NSQ NSCLC): post hoc analysis from a Phase 1 first-in-human (FIH) study in patients (pts) with brain metastases." Abstract presented at Europoean Society for Medical Oncology Congress, 2026. Madrid, Spain.
3 Chiang A, Jahchan N, Faivre E, et al. "ABBV-706: A First-in-Class SEZ6-Targeted Topoisomerase 1 Inhibitor (Top1i)-Antibody-Drug Conjugate (ADC) With Robust Antitumour Activity in Relapsed/Refractory Small Cell Lung Cancer (R/R SCLC)." Abstract presented at European Society of Medical Oncology Congress, 2026. Madrid, Spain.
4 Peer A, Tolcher A, Joshua A, et al. "Baseline molecular characterization and responses associated with ABBV-969 treatment in patients with metastatic castration-resistant prostate cancer." Abstract presented at European Society of Medical Oncology Congress, 2026. Madrid, Spain
5 Yu J, Sun Y, Wen Q, et al. "RC148 (ABBV-1480) monotherapy or in combination with docetaxel in first- or second-line advanced non-small-cell lung cancer (NSCLC) without actionable genomic alterations (AGA): updated results from a Phase 1/2 study." Abstract presented at European Society of Medical Oncology Congress, 2026. Madrid, Spain.
SOURCE AbbVie